Rigel Initiates Clinical Trial Of R348 For Rheumatoid Arthritis, Psoriasis

Armen Hareyan's picture
Advertisement

Rigel Pharmaceuticals has begun enrolling patients in a Phase 1 study to evaluate the safety and tolerability of R348, an orally available, potent inhibitor of Janus Kinase 3 (JAK3), as a potential treatment for patients with rheumatoid arthritis (RA), psoriasis and other immune disorders.

Advertisement

In preclinical studies, R348 was shown to be effective in reducing arthritic symptoms, bone destruction and swelling. It has also shown efficacy in models of psoriasis and transplant rejection. This is Rigel's fourth novel product candidate in clinical trials.

"R348 enters the clinic at a time when Rigel's product portfolio is demonstrating its potential contribution to the field of immunology," said Donald G. Payan, M.D., executive vice president and chief scientific officer at Rigel. "With R348 targeting T-cells and our oral syk kinase inhibitor, R788, targeting B-cells and other immune cells, Rigel has mounted a comprehensive assault on autoimmune disorders," he added.

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.
Advertisement